Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy

NCT03762850 is registered in ClinicalTrials.gov with Travere Therapeutics, Inc. as lead sponsor.

NCT NCT03762850
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03762850 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy
Lead sponsor
Travere Therapeutics, Inc.
Phase
Phase 3
Overall status
Completed
Start date
December 11, 2018
Completion date
August 19, 2026
Enrollment
406 (actual)
Sites
162

Conditions

As the registry lists them; a condition with its own page is linked.

immunoglobulin a nephropathy